Sign inJoin waitlistJoin the waitlist

John McCann

Associate Medical Director, Oncology · UMass Chan - Baystate

Credentials: · · ·

History

Oncology · UMass Chan - Baystate
Present
Oncology · Baystate Health
Present
UMass Chan - Baystate
Present

Tufts Medical Center
1995–1997
New England Medical Center*
1994–1995
Internal Medicine
Tufts Medical Center
1988–1991
New England Medical Center*
1988–1991
University of Massachusetts Medical School
1984–1988

Research

Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508
Journal of Clinical Oncology · 2019 · 58 citations
Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's…
Bone Marrow Transplantation · 1999 · 27 citations
High degree of occult tumor contamination in bone marrow and peripheral blood stem cells of patients undergoing autologous transplantation for non-Hodgkin's lymphoma
Biology of Blood and Marrow Transplantation · 1996 · First of 6 authors · 22 citations

DS
David Schenkein
2 papers
KM
Kenneth Miller
2 papers
AL
Alan Lyss
1 paper
CB
Chandra Belani
1 paper
GN
Gopakumar Nambudiri
1 paper
JP
James Polga
1 paper
JR
Jan Rothman
1 paper
Jerome Winegarden
1 paper
JS
Joan Schiller
1 paper
Joel Saltzman
1 paper
LH
Leora Horn
1 paper
Mohammed Kassem
1 paper

Clinical trials

Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer
Principal investigator · Terminated · Phase 2
Tufts Medical Center
2005–2006
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2, Phase 3
SWOG Cancer Research Network
2025–2028
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2039
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Site PI · Recruiting · Phase 2
Alliance for Clinical Trials in Oncology
2025–2034